SCHEMBL3370422

SCHEMBL3370422

CCOC(=O)C(OC(C)C)C(O)c1ccc(OCc2ccccc2)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 4/20 0.49
FFAR1 O14842 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
LMNA P02545 2/20 0.43
S1PR5 Q9H228 1/20 0.41
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PPARD Q03181 2/20 0.39
CTSA P10619 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
ERN1 O75460 1/20 0.38
KDM4E B2RXH2 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4331809 0.82 LMNA (0.51) FFAR1L3MBTL1LMNASMN1; SMN2
SCHEMBL3372780 0.79 S1PR5 (0.47) MRGPRX4FFAR1L3MBTL1LMNAS1PR5
SCHEMBL5379628 0.78 FFAR4 (0.49) MRGPRX4FFAR1L3MBTL1LMNASMN1; SMN2
SCHEMBL13248965 0.77 S1PR5 (0.51) MRGPRX4FFAR1L3MBTL1LMNAS1PR5
SCHEMBL10496142 0.76 LMNA (0.71) MRGPRX4FFAR1L3MBTL1LMNAS1PR5
SCHEMBL23179943 0.75 MRGPRX4 (0.49) MRGPRX4FFAR1L3MBTL1LMNAS1PR5
SCHEMBL22223337 0.75 MRGPRX4 (0.49) MRGPRX4FFAR1L3MBTL1LMNAS1PR5
SCHEMBL22223338 0.75 MRGPRX4 (0.49) MRGPRX4FFAR1L3MBTL1LMNAS1PR5
SCHEMBL10148264 0.74 MRGPRX4 (0.56) MRGPRX4FFAR1L3MBTL1S1PR5TDP1
SCHEMBL22223472 0.74 MRGPRX4 (0.47) MRGPRX4FFAR1LMNAS1PR5SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
EP-1537091-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2005-06-08 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed
WO-2004020420-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR MRGPRX4 1558/4885FFAR1 32/4885L3MBTL1 2050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.